| 吉西他滨联合异环磷酰胺二线治疗晚期非小细胞肺癌疗效分析 |
| |
| 引用本文： | 刘俊宝,崔成旭,远丽芳,刘伟,高春会,史书萍,汤海舰,邵竹筠. 吉西他滨联合异环磷酰胺二线治疗晚期非小细胞肺癌疗效分析[J]. 中华肿瘤防治杂志, 2011, 18(8): 624-625 |
| |
| 作者姓名： | 刘俊宝 崔成旭 远丽芳 刘伟 高春会 史书萍 汤海舰 邵竹筠 |
| |
| 作者单位： | 1. 北京朝阳区三环肿瘤医院内七病区,北京,100122
2. 中国医学科学院中国协和医科大学肿瘤医院内三病区,北京,100021 |
| |
| 摘 要： | 为了观察吉西他滨联合异环磷酰胺方案二线治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应,选取24例病理或细胞学确诊的晚期NSCLC,经紫杉类联合铂类化疗方案治疗进展的患者,采用吉西他滨1.0 g/m2,静脉滴入,d1、d8;异环磷酰胺1.2 g/m2,静脉滴入,d2～d4,21 d为1个周期,以TAX317研究结果为...
|
| 关 键 词： | 癌,非小细胞肺 药物疗法,联合 治疗效果 |
Gemcitabine combined with ifosfamide as second-line chemotherapy in advanced non-small cell lung cancer |
| |
| LIU Jun-bao,CUI Cheng-xu,YUAN Li-fang,LIU Wei,GAO Chun-hui,SHI Shu-ping,TANG Hai-jian,SHAO Zhu-jun. Gemcitabine combined with ifosfamide as second-line chemotherapy in advanced non-small cell lung cancer[J]. Chinese Journal of Cancer Prevention and Treatment, 2011, 18(8): 624-625 |
| |
| Authors: | LIU Jun-bao CUI Cheng-xu YUAN Li-fang LIU Wei GAO Chun-hui SHI Shu-ping TANG Hai-jian SHAO Zhu-jun |
| |
| Affiliation: | LIU Jun-bao1,CUI Cheng-xu2,YUAN Li-fang1,LIU Wei1,GAO Chun-hui1,SHI Shu-ping1,TANG Hai-jian1,SHAO Zhu-jun11.Department of Internal Medicine,Seventh Ward Area,Sanhuan Cancer Hospital of Chaoyang Area,Beijing 100122,P.R.China2.Department of Internal Medicine,Third Ward Area,Cancer Hospital and Institute,Chinese Academy of Medical Science,Peking Union Medical College,Beijing 100021,P.R.China |
| |
| Abstract: | The objective of this study was to evaluate the effectiveness and side effects of gemcitabine combined with ifosfamide as the second-line treatment in patients with advanced non-small cell lung cancer(NSCLC).Twenty four patients with histologically or cytologically confirmed advanced NSCLC were treated with gemcitabine(GEM) 1.0 g/m2,d1,d8,and ifosfamide(IFO) 1.2 g/m2,d2-d4(with mesna),iv.drip every 3 weeks.Treatment outcomes were compared with a historical control of results TAX317.All patients had received... |
| |
| Keywords: | carcinoma non-small cell lung drug therapy combination treatment outcome |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
